Ironwood Pharma Receives Nasdaq Deficiency Letter

Ironwood Pharma ( (IRWD) ) just unveiled an update.

On May 28, 2025, Ironwood Pharmaceuticals received a deficiency letter from Nasdaq indicating that its Class A common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until November 24, 2025, to regain compliance, failing which it may face delisting or need to transfer its listing to the Nasdaq Capital Market. Ironwood intends to monitor its stock price and consider options to meet the requirement, though there is no assurance of success.

The most recent analyst rating on (IRWD) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.

Spark’s Take on IRWD Stock

According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.

Ironwood Pharma’s overall stock score is driven primarily by its challenging financial performance and bearish technical indicators. While the recent earnings call provides some optimism with strong product demand, financial risks and valuation concerns weigh heavily on the score.

To see Spark’s full report on IRWD stock, click here.

More about Ironwood Pharma

Average Trading Volume: 3,319,909

Technical Sentiment Signal: Sell

Current Market Cap: $100.7M

See more insights into IRWD stock on TipRanks’ Stock Analysis page.